Table 1 Patient characteristics

Patients

8

(21)

30

(79)

38

(100)

Slides*

162

(20)

652

(80)

814

(100)

Age (years)

0.056

 Mean (SD)

42

(7.52)

50.23

(11.07)

48.5

(10.87)

 Median (IQR)

41

(38–48.75)

54

(46.75–56.25)

50.5

(44.5–55)

Gender

0.709

 Male

5

(63)

16

(53)

21

(55)

 Female

3

(38)

14

(47)

17

(45)

Tumor grade

< 0.001

 Grade II

8

(100)

0

(0)

8

(21)

 Grade III

0

(0)

17

(57)

17

(45)

 Grade IV

0

(0)

13

(43)

13

(34)

Histologic tumor size (cm)

0.126

 Mean (SD)

2.94

(1.03)

3.72

(1.31)

3.56

(1.29)

 Median (IQR)

2.76

(2.27–3.65)

3.96

(2.69–4.72)

3.65

(2.43–4.67)

Histologic PTBE size (cm)

< 0.001

 Mean (SD)

1.00

(0.45)

2.22

(0.54)

1.96

(0.72)

 Median (IQR)

1.15

(0.48–1.35)

2.12

(1.84–2.86)

2.00

(1.45–2.43)

Contrast enhancement

< 0.001

 Yes

0

(0)

30

(100)

30

(79)

 No

8

(100)

0

(0)

8

(21)

Lesion site

 Frontal lobe

5

(63)

16

(53)

21

(55)

 Temporal lobe

2

(25)

11

(37)

13

(34)

 Occipital lobe

1

(13)

3

(10)

4

(11)

MGMT methylation status

0.426

 Unmethylated

5

(63)

12

(40)

17

(45)

 Methylated

3

(38)

18

(60)

21

(55)

IDH mutation

0.698

 Mutated

4

(50)

12

(40)

16

(42)

 Wild type

4

(50)

18

(60)

22

(58)

1p/19q co-deletion

0.689

 Co-deleted

2

(25)

11

(37)

13

(34)

 Non-co-deleted

6

(75)

19

(63)

25

(66)